Ascletis Pharma Presents Preclinical Results for Weight Management Drugs at ObesityWeek 2026

MT Newswires Live
昨天

Ascletis Pharma (HKG:1672) presented key preclinical results for ASC48, ASC30_48 fixed dose combination, and ASC37 at ObesityWeek 2026, a Monday bourse filing showed.

The two poster presentations feature in vitro activity and oral pharmacokinetics of ASC48; weight loss data for ASC30_48; and extended pharmacokinetics, in vitro insulin secretion activity, and weight-loss activity of ASC37.

ObesityWeek 2026 is being held in Washington, DC, from Nov. 14 to 17.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10